Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Italiano

Showing results (251-260 of 418) with videos related to

Pageof 42
Sort By:
Cancer Research|August 29, 2020
High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 TreatmentLissete Sánchez-Magraner, James Miles, Claire L Baker, et al.
BMC Cancer|February 8, 2013
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use programJean-Yves Blay, Antoine Italiano, Isabelle Ray-Coquard, et al.
Scientific Reports|October 21, 2025
Multimodal prediction of metastatic relapse using federated deep learning in soft-tissue sarcoma with a complex genomic profileCharles Maussion, Jean-Michel Coindre, Jean-Yves Blay, et al.
Investigational New Drugs|June 28, 2021
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumorsAntoine Italiano, Wilson H Miller, Jean-Yves Blay, et al.
Ebiomedicine|November 30, 2020
High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapiesMaud Toulmonde, Carlo Lucchesi, Stéphanie Verbeke, et al.
Bulletin Du Cancer|January 18, 2021
Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ networkEmmanuelle Bompas, Valentine Martin, Fatima Meniai, et al.
The Lancet. Oncology|February 15, 2015
Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trialAxel Le Cesne, Jean-Yves Blay, Julien Domont, et al.
The Lancet. Respiratory Medicine|April 20, 2018
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trialPatrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven MalignanciesFrancesco Facchinetti, Yohann Loriot, Floriane Brayé, et al.
The Oncologist|January 31, 2012
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)Isabelle Ray-Coquard, Antoine Italiano, Emmanuelle Bompas, et al.
Pageof 42

Showing results (251-260 of 418) with videos related to

Sort By:
Pageof 42
Cancer Research|August 29, 2020
High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 TreatmentLissete Sánchez-Magraner, James Miles, Claire L Baker, et al.
BMC Cancer|February 8, 2013
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use programJean-Yves Blay, Antoine Italiano, Isabelle Ray-Coquard, et al.
Scientific Reports|October 21, 2025
Multimodal prediction of metastatic relapse using federated deep learning in soft-tissue sarcoma with a complex genomic profileCharles Maussion, Jean-Michel Coindre, Jean-Yves Blay, et al.
Investigational New Drugs|June 28, 2021
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumorsAntoine Italiano, Wilson H Miller, Jean-Yves Blay, et al.
Ebiomedicine|November 30, 2020
High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapiesMaud Toulmonde, Carlo Lucchesi, Stéphanie Verbeke, et al.
Bulletin Du Cancer|January 18, 2021
Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ networkEmmanuelle Bompas, Valentine Martin, Fatima Meniai, et al.
The Lancet. Oncology|February 15, 2015
Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trialAxel Le Cesne, Jean-Yves Blay, Julien Domont, et al.
The Lancet. Respiratory Medicine|April 20, 2018
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trialPatrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven MalignanciesFrancesco Facchinetti, Yohann Loriot, Floriane Brayé, et al.
The Oncologist|January 31, 2012
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)Isabelle Ray-Coquard, Antoine Italiano, Emmanuelle Bompas, et al.
Pageof 42